Logo image of ALGEN.PA

GENOWAY SA (ALGEN.PA) Stock Price, Quote, News and Overview

EPA:ALGEN - Euronext Paris - Matif - FR0004053510 - Common Stock - Currency: EUR

3.46  +0.05 (+1.47%)

ALGEN.PA Quote, Performance and Key Statistics

GENOWAY SA

EPA:ALGEN (3/7/2025, 7:00:00 PM)

3.46

+0.05 (+1.47%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.69
52 Week Low2.84
Market Cap32.80M
Shares9.48M
Float5.90M
Yearly DividendN/A
Dividend YieldN/A
PE24.71
Fwd PE33.59
Earnings (Next)N/A N/A
IPO05-04 2007-05-04


ALGEN.PA short term performance overview.The bars show the price performance of ALGEN.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10

ALGEN.PA long term performance overview.The bars show the price performance of ALGEN.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -2 -4 -6 -8 -10

The current stock price of ALGEN.PA is 3.46 EUR. In the past month the price increased by 4.53%. In the past year, price decreased by -10.13%.

GENOWAY SA / ALGEN Daily stock chart

ALGEN.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.07 346.68B
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 15.84 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
ARGX.BR ARGENX SE 253.61 33.75B
22UA.DE BIONTECH SE-ADR N/A 24.36B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.39 19.21B
0QF.DE MODERNA INC N/A 13.19B

About ALGEN.PA

Company Profile

ALGEN logo image genOway SA engages in the development of genetically-modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 128 full-time employees. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.

Company Info

GENOWAY SA

Technopark 2, 31 Rue Saint Jean-de-Dieu

Lyon AUVERGNE-RHONE-ALPES FR

Employees: 128

Company Website: https://www.genoway.com/

Investor Relations: http://www.genoway.com/about/investors/ctinvestors-relation.htm

Phone: 33437654100

GENOWAY SA / ALGEN.PA FAQ

What is the stock price of GENOWAY SA today?

The current stock price of ALGEN.PA is 3.46 EUR. The price increased by 1.47% in the last trading session.


What is the ticker symbol for GENOWAY SA stock?

The exchange symbol of GENOWAY SA is ALGEN and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALGEN.PA stock listed?

ALGEN.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for GENOWAY SA stock?

9 analysts have analysed ALGEN.PA and the average price target is 6.12 EUR. This implies a price increase of 76.88% is expected in the next year compared to the current price of 3.46. Check the GENOWAY SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GENOWAY SA worth?

GENOWAY SA (ALGEN.PA) has a market capitalization of 32.80M EUR. This makes ALGEN.PA a Nano Cap stock.


How many employees does GENOWAY SA have?

GENOWAY SA (ALGEN.PA) currently has 128 employees.


What are the support and resistance levels for GENOWAY SA (ALGEN.PA) stock?

GENOWAY SA (ALGEN.PA) has a support level at 3.37 and a resistance level at 3.46. Check the full technical report for a detailed analysis of ALGEN.PA support and resistance levels.


Is GENOWAY SA (ALGEN.PA) expected to grow?

The Revenue of GENOWAY SA (ALGEN.PA) is expected to grow by 9.95% in the next year. Check the estimates tab for more information on the ALGEN.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GENOWAY SA (ALGEN.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GENOWAY SA (ALGEN.PA) stock pay dividends?

ALGEN.PA does not pay a dividend.


What is the Price/Earnings (PE) ratio of GENOWAY SA (ALGEN.PA)?

The PE ratio for GENOWAY SA (ALGEN.PA) is 24.71. This is based on the reported non-GAAP earnings per share of 0.14 and the current share price of 3.46 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ALGEN.PA.


ALGEN.PA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ALGEN.PA. When comparing the yearly performance of all stocks, ALGEN.PA is a bad performer in the overall market: 87% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALGEN.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ALGEN.PA. While ALGEN.PA belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALGEN.PA Financial Highlights

Over the last trailing twelve months ALGEN.PA reported a non-GAAP Earnings per Share(EPS) of 0.14. The EPS decreased by -20.89% compared to the year before.


Industry RankSector Rank
PM (TTM) 5.86%
ROA 3.96%
ROE 7.06%
Debt/Equity 0.26
Chartmill High Growth Momentum
EPS Q2Q%-29.99%
Sales Q2Q%14.77%
EPS 1Y (TTM)-20.89%
Revenue 1Y (TTM)15.03%

ALGEN.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ALGEN.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of -20% and a revenue growth 9.95% for ALGEN.PA


Ownership
Inst Owners5.68%
Ins Owners9.39%
Short Float %N/A
Short RatioN/A
Analysts
Analysts86.67
Price Target6.12 (76.88%)
EPS Next Y-20%
Revenue Next Year9.95%